Wells Fargo & Company Heron Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding HRTX
# of Institutions
179Shares Held
121MCall Options Held
80.4KPut Options Held
94.9K-
Rubric Capital Management LP New York, NY26.7MShares$41.4 Million1.48% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.85MShares$13.7 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.72MShares$13.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.33MShares$12.9 Million0.0% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA6.99MShares$10.8 Million28.8% of portfolio
About HERON THERAPEUTICS, INC.
- Ticker HRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,774,000
- Market Cap $184M
- Description
- Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...